$BLTE News

Belite Bio Announces Uplisting to the Nasdaq Global Select Market

Belite Bio Wins Nasdaq Global Select Listing, Trading Starts Oct. 19

Belite Bio Stock In Focus After Stargardt Drug Filings In Three Markets

Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1

Belite Bio Files Marketing Authorization Application In Singapore, U.K., Switzerland For Tinlarebant To Treat Stargardt Disease Type 1

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross

Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234

Belite Bio On Track For A Potential Blockbuster Launch In 2027

HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

Belite Bio Submits Japanese New Drug Application For Tinlarebant In Stargardt Disease Type 1

Why Is Belite Bio Stock Soaring Friday?

This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303

Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease

Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 - Slideshow

Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 Transcript